On June 10, 2014, Sumit K. Subudhi, M.D., Ph.D., an assistant professor at The University of Texas MD Anderson Cancer Center, discussed current immunotherapy treatment options for patients with prostate, bladder, and kidney cancers, and how close we are to making these treatments available to more patients.
This 45-minute online webinar, which is part of the Cancer Research Institute's Breakthroughs in Cancer Immunotherapy webinar series, was generously supported by Dendreon.
Dr. Subudhi is a clinical Advanced Scholar Instructor at The University of Texas MD Anderson Cancer Center, where he currently investigates novel immunotherapy strategies in prostate cancer. Dr. Subudhi attended the University of Chicago Pritzker School of Medicine, where his thesis work focused on examining the role of the immune checkpoint PD-L1 in regulating T cell-mediated immune responses. He trained in internal medicine at New York Presbyterian Hospital-Weill Cornell Medical College, and he completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. During his residency, he examined immunological biomarkers in melanoma patients treated with ipilimumab (anti-CTLA-4), and joined Dr. Allison’s laboratory as a medical oncology fellow to study whether this approach could work in animal models of prostate cancer. He continues to pursue these research interests while designing novel clinical trials in castration-resistant prostate cancer.